

ADAMS JULIAN
Form 4
October 30, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ADAMS JULIAN

2. Issuer Name and Ticker or Trading Symbol
INFINITY PHARMACEUTICALS, INC. [INFI]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
President, R&D & CSO

(Last) (First) (Middle)

C/O INFINITY
PHARMACEUTICALS, INC., 780
MEMORIAL DRIVE

3. Date of Earliest Transaction
(Month/Day/Year)
10/28/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

CAMBRIDGE, MA 02139

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock	10/28/2008		M		54,727 (1) \$ 2.04	180,257	D
Common Stock	10/28/2008		M		54,727 (2) \$ 2.04	234,984	D
Common Stock	10/28/2008		M		331 \$ 3.48	235,315	D
Common Stock	10/28/2008		M		27,628 (3) \$ 3.48	262,943	D

Edgar Filing: ADAMS JULIAN - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 2.04	10/28/2008		M	54,727	<u>(4)</u> 05/10/2015	Common Stock	54,727
Stock Option (right to buy)	\$ 2.04	10/28/2008		M	54,727	<u>(5)</u> 05/10/2015	Common Stock	54,727
Stock Option (right to buy)	\$ 3.48	10/28/2008		M	331	<u>(6)</u> 03/31/2016	Common Stock	331
Stock Option (right to buy)	\$ 3.48	10/28/2008		M	27,628	<u>(7)</u> 03/31/2016	Common Stock	27,628

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ADAMS JULIAN C/O INFINITY PHARMACEUTICALS, INC. 780 MEMORIAL DRIVE CAMBRIDGE, MA 02139			President, R&D & CSO	

Signatures

/s/ Julian Adams

10/30/2008

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares were acquired upon the exercise of a stock option which was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity Pharmaceuticals, Inc. (?Infinity?) that lapses in accordance with the vesting schedule of the original option. Of such 54,727 shares, 34,205 shares were vested as of the date of exercise of the stock option and the remaining 20,522 shares are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option, which schedule was as follows: the option vested monthly in equal installments for six years, beginning on January 31, 2005.

(2) The shares were acquired upon the exercise of a stock option which was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option. Of such 54,727 shares, 51,306 shares were vested as of the date of exercise of the stock option and the remaining 3,421 shares are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option, which schedule was as follows: the option vested monthly in equal installments for four years, beginning on January 31, 2005.

(3) The shares were acquired upon the exercise of a stock option which was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option. Of such 27,628 shares, 18,994 shares were vested as of the date of exercise of the stock option and the remaining 8,634 shares are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option, which schedule was as follows: the option vested annually in equal installments for four years, beginning on February 1, 2006.

(4) The stock option was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option. The optionee exercised the stock option in full. The vesting schedule of the original option was as follows: the option vested monthly in equal installments for six years, beginning on January 31, 2005. As such, as of the date of exercise, the option was vested as to 34,205 shares. A Form 4 previously filed on September 13, 2006 inadvertently reported the vesting schedule of the stock option as annual, rather than monthly, vesting.

(5) The stock option was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option. The optionee exercised the stock option in full. The vesting schedule of the original option was as follows: the option vested monthly in equal installments for four years, beginning on January 31, 2005. As such, as of the date of exercise, the option was vested as to 51,306 shares. A Form 4 previously filed on September 13, 2006 inadvertently reported the vesting schedule of the stock option as annual, rather than monthly, vesting.

(6) The stock option vested in equal monthly installments for 1 year, beginning on February 1, 2006.

(7) The stock option was subject to a right of early exercise, pursuant to which the optionee could exercise unvested stock options and receive, in lieu thereof, shares of restricted stock that are subject to a right of repurchase by Infinity that lapses in accordance with the vesting schedule of the original option. The optionee exercised the stock option in full. The vesting schedule of the original option was as follows: the option vested annually in equal installments for four years, beginning on February 1, 2006. As such, as of the date of exercise, the option was vested as to 18,994 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.